Lyra Therapeutics, Inc.LYRAEarnings & Financial Report
Lyra Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative, long-acting, locally delivered therapies for ear, nose, and throat (ENT) conditions. Its lead product candidates target chronic rhinosinusitis, addressing unmet medical needs for patients who do not get relief from standard treatments, with core operations based in the United States.
LYRA Q2 FY2025 Key Financial Metrics
Revenue
$183.0K
Gross Profit
N/A
Operating Profit
$-8.8M
Net Profit
$-7.4M
Gross Margin
N/A
Operating Margin
-4823.0%
Net Margin
-4063.9%
YoY Growth
-69.4%
EPS
$-5.51
Lyra Therapeutics, Inc. Q2 FY2025 Financial Summary
Lyra Therapeutics, Inc. reported revenue of $183.0K (down 69.4% YoY) for Q2 FY2025, with a net profit of $-7.4M (up 84.5% YoY) (-4063.9% margin).
Key Financial Metrics
| Total Revenue | $183.0K |
|---|---|
| Net Profit | $-7.4M |
| Gross Margin | N/A |
| Operating Margin | -4823.0% |
| Report Period | Q2 FY2025 |
Lyra Therapeutics, Inc. Annual Revenue by Year
Lyra Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $1.5M).
Lyra Therapeutics, Inc. Quarterly Revenue & Net Profit History
Lyra Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2025 | $183.0K | -69.4% | $-7.4M | -4063.9% |
| Q1 FY2025 | $183.0K | -65.6% | $-8.5M | -4670.5% |
| Q4 FY2024 | $209.0K | +43.2% | $-11.0M | -5253.1% |
| Q3 FY2024 | $195.0K | -64.2% | $-11.9M | -6088.7% |
| Q2 FY2024 | $598.0K | +30.6% | $-48.1M | -8048.7% |
| Q1 FY2024 | $532.0K | +29.8% | $-22.5M | -4220.3% |
| Q4 FY2023 | $146.0K | +1227.3% | $-15.2M | -10380.8% |
| Q3 FY2023 | $544.0K | +51.5% | $-15.7M | -2877.0% |
Income Statement
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $544000 | $146000 | $532000 | $598000 | $195000 | $209000 | $183000 | $183000 |
| YoY Growth | 51.5% | 1227.3% | 29.8% | 30.6% | -64.2% | 43.2% | -65.6% | -69.4% |
Balance Sheet
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $120.6M | $142.6M | $141.5M | $94.6M | $78.8M | $66.3M | $56.3M | $52.6M |
| Liabilities | $36.3M | $53.2M | $64.0M | $63.6M | $58.1M | $54.8M | $52.4M | $51.0M |
| Equity | $84.2M | $89.4M | $77.5M | $31.0M | $20.6M | $11.6M | $3.9M | $1.6M |
Cash Flow
| Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-14.1M | $-19.1M | $-22.5M | $-20.0M | $-16.2M | $-11.4M | $-8.8M | $-6.6M |